Gastroretentive Drug Delivery Systems Outsourcing Market Size & Growth Forecast 2027–2036, By Segments (Dosage Form), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Gastroretentive Drug Delivery Systems Outsourcing Market size was worth USD 1.69 billion in 2026 and is poised to grow at a 6.64% CAGR between 2027 and 2036, crossing USD 3.21 billion by 2036. The industry revenue for 2027 is assessed at USD 1.78 billion.
Get more details on this report
Request Free Sample ReportGastroretentive Drug Delivery Systems Outsourcing Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 49.82% share, driven by mature pharmaceutical outsourcing ecosystem, strong CDMO presence, and demand for complex gastroretentive formulation and development services under strict regulatory standards
- Asia Pacific growth driven by rising pharma manufacturing activity, expanding contract service providers, and cost-competitive outsourcing hubs supporting advanced oral drug delivery programs, with 8.02% CAGR
Segment Momentum
- Tablets held a 40.28% share in 2026 because they benefit from established manufacturing workflows, broad provider familiarity, and efficient scale-up and process control capabilities.
- Capsule is the fastest-growing dosage form as sponsors increasingly seek formulation flexibility and customized gastroretentive designs that support evolving development requirements.
Market Expansion Drivers
- Rising pharmaceutical outsourcing demand for advanced controlled-release formulation development.
- Increasing prevalence of gastric and ulcer-related diseases driving targeted drug delivery need.
- Advancements in polymer science and bioavailability enhancement improving drug retention performance.
Leading Market Participants
- Top companies in the gastroretentive drug delivery systems outsourcing market include Catalent, Inc. (United States), Lonza Group AG (Switzerland), Evonik Industries AG (Germany), Colorcon, Inc. (United States), Quotient Sciences Limited (United Kingdom), Aenova Group GmbH (Germany), Evotec SE (Germany), Ashland Inc. (United States), Vectura Group plc (United Kingdom).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.69 billion
- 2027 Estimated Market Size: USD 1.78 billion.
- Projected Market Size: USD 3.21 billion by 2036
- Growth Forecast: 6.64% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Tablets (Dosage Form)
- Emerging Opportunity Segment: Capsule (Dosage Form)
Market Growth Drivers and Industry Trends
Rising pharmaceutical outsourcing demand for advanced controlled-release formulation development
The gastroretentive drug delivery systems outsourcing market is benefiting from pharmaceutical companies seeking external expertise for the development of sophisticated controlled-release formulations. Gastroretentive technologies require specialized knowledge spanning formulation design, drug release kinetics, excipient selection, manufacturing processes, and performance evaluation, encouraging drug developers to collaborate with contract development and manufacturing organizations. Outsourcing can also provide access to specialized formulation infrastructure and technical capabilities without requiring pharmaceutical companies to build equivalent internal resources. As drug developers focus internal teams on core research and commercialization activities, external formulation partners are increasingly involved in complex oral drug delivery development programs.
Increasing prevalence of gastric and ulcer-related diseases driving targeted drug delivery need
Growing demand for targeted treatment of gastric and ulcer-related conditions is supporting the gastroretentive drug delivery systems outsourcing market because these therapies can benefit from prolonged drug residence in the stomach. Conventional oral dosage forms may pass rapidly through the gastrointestinal tract, potentially limiting localized exposure for medicines intended to act within the stomach or upper gastrointestinal region. Gastroretentive approaches can help maintain drug presence at the desired site for longer periods, supporting controlled release and potentially improving therapeutic utilization. Pharmaceutical developers therefore have greater incentive to access external formulation expertise for developing dosage forms designed around gastric retention and sustained drug delivery requirements.
Advancements in polymer science and bioavailability enhancement improving drug retention performance
Advances in polymer science are strengthening the gastroretentive drug delivery systems outsourcing market by enabling the design of formulations with improved adhesion, swelling, buoyancy, and controlled-release characteristics. Newer polymer combinations and formulation strategies can be tailored to regulate drug release while helping dosage forms remain within the gastrointestinal tract for extended periods. These developments are particularly relevant for compounds with poor solubility, limited absorption windows, or stability and bioavailability challenges that may benefit from prolonged gastrointestinal exposure. Specialized outsourcing providers can support pharmaceutical developers in screening polymers, optimizing formulation parameters, and evaluating drug release and retention characteristics during development.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising pharmaceutical outsourcing demand for advanced controlled-release formulation development | 2.00% | Moderate | North America, Asia Pacific | High | Near Term |
| Increasing prevalence of gastric and ulcer-related diseases driving targeted drug delivery need | 1.70% | High | Global | High | Mid Term |
| Advancements in polymer science and bioavailability enhancement improving drug retention performance | 1.50% | Moderate | North America, Europe | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for the largest share of 49.82% in 2026 in the gastroretentive drug delivery systems outsourcing market, reflecting the region's strong pharmaceutical development ecosystem, advanced drug-delivery research capabilities, and established outsourcing infrastructure. Pharmaceutical and biotechnology companies increasingly rely on specialized external partners for formulation development, analytical testing, clinical support, and manufacturing activities, allowing them to access technical expertise while improving development efficiency. Demand for gastroretentive technologies is also supported by the need to enhance drug absorption, prolong therapeutic exposure, and improve dosing convenience for medicines affected by limited gastrointestinal residence time. Strong research activity in advanced formulations and well-developed regulatory and quality frameworks further reinforce North America's position in outsourced development services.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is experiencing the fastest growth as pharmaceutical manufacturing capacity, formulation expertise, and contract development capabilities continue to expand across the region. The increasing presence of generic drug manufacturers and emerging pharmaceutical developers is creating greater demand for specialized delivery technologies that can improve product performance and differentiation. Investments in research infrastructure and high-quality manufacturing facilities are strengthening regional capabilities in complex formulation development, while cost considerations encourage pharmaceutical companies to outsource selected development and production activities. Growing healthcare needs and expanding pharmaceutical markets are also creating favorable conditions for broader adoption of gastroretentive delivery systems and related outsourcing services.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Manufacturing ExpertiseGermany supports gastroretentive drug delivery outsourcing through advanced pharmaceutical manufacturing infrastructure and strong process validation capabilities. Outsourcing providers in Germany focus on reliable scale-up and consistent production quality for complex oral formulations.
France 🇫🇷
Specialized Development ServicesFrance supports outsourcing demand through pharmaceutical research expertise and contract development services focused on complex oral drug delivery. Companies in France continue collaborating with external formulation specialists to streamline product development activities.
Italy 🇮🇹
Flexible Manufacturing SupportItaly is expanding outsourced pharmaceutical manufacturing for gastroretentive drug delivery systems with an emphasis on adaptable production and formulation support. Contract manufacturers in Italy continue strengthening capabilities for specialized oral dosage technologies.
Japan 🇯🇵
Advanced Oral FormulationsJapan continues expanding outsourced development for gastroretentive drug delivery systems by emphasizing sophisticated formulation technologies and stringent quality requirements. Pharmaceutical innovators in Japan collaborate with specialized partners to optimize product performance and manufacturing efficiency.
South Korea 🇰🇷
CDMO Capability ExpansionSouth Korea is strengthening its contract development and manufacturing ecosystem for gastroretentive drug delivery systems. Outsourcing providers in South Korea are broadening formulation expertise and production flexibility to support pharmaceutical development projects.
United States 🇺🇸
Formulation Development HubThe U.S. remains an important outsourcing destination for gastroretentive drug delivery development due to its specialized formulation expertise and contract development capabilities. Pharmaceutical companies in the U.S. increasingly seek partners that can accelerate complex oral dosage innovation.
Segment Leadership and Growth Trends
Gastroretentive Drug Delivery Systems Outsourcing Market Share (%), by Dosage Form, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportDosage Form Segment Analysis: Tablets (Largest Segment) vs Capsule (Fastest-Growing Segment)
Tablets dominated the gastroretentive drug delivery systems outsourcing market, accounting for a 40.28% share in 2026, supported by their established use in oral drug delivery and their compatibility with gastroretentive formulations designed to prolong drug residence in the stomach. Tablets offer formulation flexibility, controlled-release capabilities, and relatively straightforward manufacturing processes, making them attractive for outsourcing pharmaceutical development and production activities. Their suitability for incorporating technologies that regulate drug release and improve therapeutic exposure further strengthens demand from pharmaceutical developers seeking specialized gastroretentive solutions. In addition, established manufacturing expertise and familiarity with tablet-based dosage forms facilitate technology transfer and scale-up, reinforcing their leading position within outsourced gastroretentive drug delivery development.
The capsule segment is experiencing the fastest growth as pharmaceutical developers increasingly explore flexible dosage platforms for gastroretentive formulations requiring specialized release characteristics and targeted drug retention. Capsules can accommodate different formulation approaches and internal delivery systems, creating opportunities for the development of innovative gastroretentive products tailored to specific therapeutic requirements. Growing interest in improving drug absorption, extending therapeutic action, and addressing medicines with limited absorption windows is encouraging outsourcing partners to provide advanced capsule formulation and development capabilities. The increasing complexity of gastroretentive technologies is also making specialized contract development and manufacturing expertise more valuable, supporting stronger adoption of capsule-based solutions.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Dosage Form | Tablets, Liquid, Microspheres, Capsule, Others | Tablets | Capsule |
Competitive Landscape and Market Positioning
Leading companies in the gastroretentive drug delivery systems outsourcing market:
1. Catalent Inc. (United States)
2. Lonza Group AG (Switzerland)
3. Evonik Industries AG (Germany)
4. Colorcon Inc. (United States)
5. Quotient Sciences Limited (United Kingdom)
6. Aenova Group GmbH (Germany)
7. Evotec SE (Germany)
8. Ashland Inc. (United States)
9. Vectura Group plc (United Kingdom)
The gastroretentive drug delivery systems outsourcing market is witnessing growing demand for specialized formulation services, controlled-release technologies, and advanced manufacturing support. Organizations are strengthening outsourcing capabilities to accelerate drug development timelines and improve therapeutic performance. Continuous innovation in gastric retention technologies is also shaping the competitive landscape of the market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Catalent Inc. (United States) | |||||||
| Lonza Group AG (Switzerland) | |||||||
| Evonik Industries AG (Germany) | |||||||
| Colorcon Inc. (United States) | |||||||
| Quotient Sciences Limited (United Kingdom) | |||||||
| Aenova Group GmbH (Germany) | |||||||
| Evotec SE (Germany) | |||||||
| Ashland Inc. (United States) | |||||||
| Vectura Group plc (United Kingdom). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| LGM Pharma | Mar-25 | LGM Pharma completed a USD 6 million investment to expand its United States-based production capacity for advanced gastric retentive formulations. This capital expenditure is intended to bolster the company's manufacturing footprint and support growing demand for specialized drug delivery technologies within the pharmaceutical outsourcing sector. |
| Lonza | Dec-24 | Lonza commissioned new capsule manufacturing facilities in India and China to scale production capacity for modified-release products. This geographic expansion strengthens the company's global supply chain network, enabling enhanced support for pharmaceutical partners requiring advanced drug delivery solutions to meet increasing market demand. |
| Amneal Pharmaceuticals | Apr-24 | Amneal Pharmaceuticals secured a strategic grant to support the development of an extended-release pyridostigmine gastric retentive tablet. This project represents a targeted investment in the commercialization of specialized oral delivery technologies, potentially enhancing the company's product portfolio and strengthening its competitive position in the niche gastroretentive drug delivery market. |
| Catalent | Aug-22 | Catalent entered a definitive agreement to acquire Metrics Contract Services for USD 475 million. This strategic acquisition enhances Catalent’s high-potential capabilities in integrated oral solid formulation, significantly increasing its development and manufacturing capacity to simplify and accelerate complex drug delivery programs for pharmaceutical clients. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Gastroretentive Drug Delivery Systems Outsourcing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Outsourcing Service Model | Contract Development Services, Contract Manufacturing Services, Integrated Development & Manufacturing Services |
| Client Type | Pharmaceutical Companies, Biotechnology Companies, Generic & Specialty Drug Manufacturers |
| Development Stage | Preclinical Development, Clinical Development, Commercial Manufacturing |
Gastroretentive Drug Delivery Systems Outsourcing Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| CDMO Capability Benchmarking for Gastroretentive Technologies |
|
| Outsourcing Decision Framework for Oral Drug Delivery |
|
| Technology Licensing and Partnership Landscape |
|
Need a different cut of the data?
Request Custom ResearchHow much revenue does the gastroretentive drug delivery systems outsourcing market generate?
How much is the gastroretentive drug delivery systems outsourcing industry expected to grow by 2036?
Why are pharmaceutical companies increasing outsourcing for gastroretentive drug formulation development?
How are advances in polymer science influencing the gastroretentive drug delivery systems outsourcing market?
Why are tablets the preferred dosage form in the gastroretentive drug delivery systems outsourcing market?
What is driving growth in capsule outsourcing services?
Why does North America dominate the gastroretentive drug delivery systems outsourcing market?
What factors are driving Asia Pacific’s growth in gastroretentive drug delivery outsourcing?
What are the prominent companies operating in the gastroretentive drug delivery systems outsourcing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization